CA1060903A - Pharmaceutically useful indanylpropionic acid derivatives - Google Patents
Pharmaceutically useful indanylpropionic acid derivativesInfo
- Publication number
- CA1060903A CA1060903A CA219,910A CA219910A CA1060903A CA 1060903 A CA1060903 A CA 1060903A CA 219910 A CA219910 A CA 219910A CA 1060903 A CA1060903 A CA 1060903A
- Authority
- CA
- Canada
- Prior art keywords
- acid
- group
- isopropylindan
- formula
- ethylindan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- JLPVOZGNXQAVSI-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-1-yl)propanoic acid Chemical class C1=CC=C2C(C(C)C(O)=O)CCC2=C1 JLPVOZGNXQAVSI-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- -1 ethyl 2-(2-ethylindan-5-yl)propionate Chemical compound 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- PXLGRXCUTTXRSC-UHFFFAOYSA-N 2-(2-propan-2-yl-2,3-dihydro-1H-inden-5-yl)propanenitrile Chemical compound C1=C(C(C)C#N)C=C2CC(C(C)C)CC2=C1 PXLGRXCUTTXRSC-UHFFFAOYSA-N 0.000 claims description 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- VTZRAFPPVSWWJU-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1h-inden-5-yl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=C2CC(CC)CC2=C1 VTZRAFPPVSWWJU-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- RYDUZJFCKYTEHX-UHFFFAOYSA-N 2-(2-propan-2-yl-2,3-dihydro-1h-inden-5-yl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=C2CC(C(C)C)CC2=C1 RYDUZJFCKYTEHX-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- HMNGMAOTIXZBMA-UHFFFAOYSA-N 2-(2-propan-2-yl-2,3-dihydro-1H-inden-5-yl)propanamide Chemical compound C(C)(C)C1CC2=CC=C(C=C2C1)C(C(=O)N)C HMNGMAOTIXZBMA-UHFFFAOYSA-N 0.000 claims description 4
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical class C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 claims description 2
- IEHKZGIZWPEDDG-UHFFFAOYSA-M sodium;2-(2-ethyl-2,3-dihydro-1h-inden-5-yl)propanoate Chemical compound [Na+].C1=C(C(C)C([O-])=O)C=C2CC(CC)CC2=C1 IEHKZGIZWPEDDG-UHFFFAOYSA-M 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- CVDGDNNPUOUDLT-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1H-inden-5-yl)propanoic acid piperidine Chemical compound C1CCNCC1.CCC1CC2=CC=C(C=C2C1)C(C)C(O)=O CVDGDNNPUOUDLT-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- GBFGQDKPGXETPZ-UHFFFAOYSA-N ethyl 2-(2-propan-2-yl-2,3-dihydro-1h-inden-5-yl)propanoate Chemical compound CCOC(=O)C(C)C1=CC=C2CC(C(C)C)CC2=C1 GBFGQDKPGXETPZ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 34
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 229940125716 antipyretic agent Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 239000000047 product Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000000921 elemental analysis Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- GVAXVLJYBFNQBX-UHFFFAOYSA-N 5-(chloromethyl)-2-propan-2-yl-2,3-dihydro-1H-indene Chemical compound C(C)(C)C1CC2=CC=C(C=C2C1)CCl GVAXVLJYBFNQBX-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- 238000005292 vacuum distillation Methods 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000012259 ether extract Substances 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- CRVLWWKYIRLIAX-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1h-inden-5-yl)acetonitrile Chemical compound C1=C(CC#N)C=C2CC(CC)CC2=C1 CRVLWWKYIRLIAX-UHFFFAOYSA-N 0.000 description 2
- NQTTVCQCAPSWHD-UHFFFAOYSA-N 2-(2-propan-2-yl-2,3-dihydro-1H-inden-5-yl)acetonitrile Chemical compound C(C)(C)C1CC2=CC=C(C=C2C1)CC#N NQTTVCQCAPSWHD-UHFFFAOYSA-N 0.000 description 2
- WVZKEIVGAZKERI-UHFFFAOYSA-N 5-(chloromethyl)-2-ethyl-2,3-dihydro-1h-indene Chemical compound C1=C(CCl)C=C2CC(CC)CC2=C1 WVZKEIVGAZKERI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FHNDXUYNRPSKDT-INIZCTEOSA-N (4as)-3-methoxy-1,4a-dimethyl-7-propan-2-yl-5,6-dihydronaphthalen-2-one Chemical compound C1CC(C(C)C)=CC2=C(C)C(=O)C(OC)=C[C@@]21C FHNDXUYNRPSKDT-INIZCTEOSA-N 0.000 description 1
- WJNBFERHVLTYOV-UHFFFAOYSA-N 2-ethyl-2,3-dihydro-1h-indene Chemical compound C1=CC=C2CC(CC)CC2=C1 WJNBFERHVLTYOV-UHFFFAOYSA-N 0.000 description 1
- HOWRLXGUHZATCY-UHFFFAOYSA-N 2-propan-2-yl-2,3-dihydro-1h-indene Chemical compound C1=CC=C2CC(C(C)C)CC2=C1 HOWRLXGUHZATCY-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 150000008522 N-ethylpiperidines Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001339 alkali metal compounds Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JPONLSOQEDZIOZ-UHFFFAOYSA-N n,n,2-trimethylnaphthalen-1-amine Chemical compound C1=CC=C2C(N(C)C)=C(C)C=CC2=C1 JPONLSOQEDZIOZ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
- C07C17/32—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by introduction of halogenated alkyl groups into ring compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP49017981A JPS50111057A (en, 2012) | 1974-02-14 | 1974-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1060903A true CA1060903A (en) | 1979-08-21 |
Family
ID=11958885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA219,910A Expired CA1060903A (en) | 1974-02-14 | 1975-02-12 | Pharmaceutically useful indanylpropionic acid derivatives |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS50111057A (en, 2012) |
| BE (1) | BE825582A (en, 2012) |
| CA (1) | CA1060903A (en, 2012) |
| CH (1) | CH605566A5 (en, 2012) |
| DE (1) | DE2501459A1 (en, 2012) |
| DK (1) | DK52975A (en, 2012) |
| ES (1) | ES434751A1 (en, 2012) |
| FR (1) | FR2261003B1 (en, 2012) |
| GB (1) | GB1502662A (en, 2012) |
| NL (1) | NL7501806A (en, 2012) |
| SE (1) | SE7501520L (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK470875A (da) * | 1974-10-29 | 1976-04-30 | Sandoz Ag | Fremgangsmade til fremstilling af benzenderivater |
| JPS56138138A (en) * | 1981-03-04 | 1981-10-28 | Hexachimie | Manufacture of indane derivative |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH592598A5 (en, 2012) * | 1973-10-30 | 1977-10-31 | Hexachimie |
-
1974
- 1974-02-14 JP JP49017981A patent/JPS50111057A/ja active Pending
-
1975
- 1975-01-15 DE DE19752501459 patent/DE2501459A1/de not_active Withdrawn
- 1975-01-27 CH CH92475A patent/CH605566A5/xx not_active IP Right Cessation
- 1975-02-05 GB GB4947/75A patent/GB1502662A/en not_active Expired
- 1975-02-11 SE SE7501520A patent/SE7501520L/xx unknown
- 1975-02-12 CA CA219,910A patent/CA1060903A/en not_active Expired
- 1975-02-13 DK DK52975*#A patent/DK52975A/da unknown
- 1975-02-14 FR FR7504755A patent/FR2261003B1/fr not_active Expired
- 1975-02-14 ES ES434751A patent/ES434751A1/es not_active Expired
- 1975-02-14 BE BE153407A patent/BE825582A/xx not_active IP Right Cessation
- 1975-02-14 NL NL7501806A patent/NL7501806A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SE7501520L (en, 2012) | 1975-08-15 |
| FR2261003B1 (en, 2012) | 1978-07-21 |
| DE2501459A1 (de) | 1975-08-21 |
| CH605566A5 (en, 2012) | 1978-09-29 |
| NL7501806A (nl) | 1975-08-18 |
| JPS50111057A (en, 2012) | 1975-09-01 |
| GB1502662A (en) | 1978-03-01 |
| ES434751A1 (es) | 1977-04-01 |
| FR2261003A1 (en, 2012) | 1975-09-12 |
| DK52975A (en, 2012) | 1975-10-13 |
| BE825582A (fr) | 1975-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4110337A (en) | Triazolobenzodiazepines | |
| FI69451B (fi) | Foerfarande foer framstaellning av antiinflammatoriska 4,5-diaryl-2-nitroimidazoler | |
| US4096267A (en) | (1-Oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio) alkanoic acids, and derivatives thereof | |
| CA1076134A (en) | Process for preparing phenylacetic acid ester derivatives | |
| US4365076A (en) | Process for the preparation of cycloalkylidenemethylphenylacetic acid derivatives | |
| JPS6036426B2 (ja) | イミダゾ−ル誘導体及びそれを有効成分とする鎮痙剤 | |
| JPS6356225B2 (en, 2012) | ||
| US3991212A (en) | Anti-inflammatory agents | |
| US4670439A (en) | 2H-1-benzopyran-2-one derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
| CA1060903A (en) | Pharmaceutically useful indanylpropionic acid derivatives | |
| GB1577342A (en) | Aminoalkyl-pyrrolobenzoxazalkanes | |
| US4116972A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
| US4767767A (en) | 2-pyrrolidinylethyl-2-(7-trifluoromethyl-4-quinolyl-aminobenzoate having analgesic, antipyretic and anti-inflammatory activities | |
| US4432991A (en) | Therapeutically active 3-amino-1-phenyl(and substituted phenyl)-2-pyrazolines | |
| US4461912A (en) | Phenylacetic acid derivatives, their preparation and compositions containing them | |
| Mase et al. | Imidazo [2, 1-b] benzothiazoles 3: syntheses and immunosuppressive activities of 2-(m-acyloxyphenyl) imidazo [2, 1-b] benzothiazoles | |
| CA2022812A1 (en) | Chalcone derivatives | |
| JPH0710863B2 (ja) | エーテル化若しくはエステル化しうるジヒドロキシ基により位置２で置換された４―ｏｈキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用 | |
| US3979468A (en) | 4'-Chloro-4-ethynylbiphenyl and method of preparing same | |
| US3281468A (en) | beta-phenyl-beta-hydroxyethylamines | |
| US4259256A (en) | 2-Benzoyl-3-dimethylamino-2-alkenonitriles | |
| US3741988A (en) | Novel benzoylphenylacetic acid esters | |
| US3780065A (en) | Phenylvulpinic acid derivatives | |
| US4436752A (en) | Treatment of gastric and gastro-duodenal disorders with derivatives of phenyl aliphatic carboxylic acids | |
| HU198915B (en) | Process for producing new 2-thiazolidinone derivatives and pharmaceutical compositions containing them |